JP2022537883A - エルトロンボパグの投与計画 - Google Patents

エルトロンボパグの投与計画 Download PDF

Info

Publication number
JP2022537883A
JP2022537883A JP2021568408A JP2021568408A JP2022537883A JP 2022537883 A JP2022537883 A JP 2022537883A JP 2021568408 A JP2021568408 A JP 2021568408A JP 2021568408 A JP2021568408 A JP 2021568408A JP 2022537883 A JP2022537883 A JP 2022537883A
Authority
JP
Japan
Prior art keywords
eltrombopag
dose
tapering
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021568408A
Other languages
English (en)
Japanese (ja)
Inventor
スタンコビッチ,ミオナ
クーパー,ニコラ
ガニマ,ウェールド
ザジャ,フランセスコ
Original Assignee
ノバルティス ファーマシューティカルズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス ファーマシューティカルズ コーポレーション filed Critical ノバルティス ファーマシューティカルズ コーポレーション
Publication of JP2022537883A publication Critical patent/JP2022537883A/ja
Priority to JP2023166306A priority Critical patent/JP2023182667A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021568408A 2019-05-14 2019-05-14 エルトロンボパグの投与計画 Withdrawn JP2022537883A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023166306A JP2023182667A (ja) 2019-05-14 2023-09-27 エルトロンボパグの投与計画

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/032171 WO2020231407A1 (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023166306A Division JP2023182667A (ja) 2019-05-14 2023-09-27 エルトロンボパグの投与計画

Publications (1)

Publication Number Publication Date
JP2022537883A true JP2022537883A (ja) 2022-08-31

Family

ID=67211802

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568408A Withdrawn JP2022537883A (ja) 2019-05-14 2019-05-14 エルトロンボパグの投与計画
JP2023166306A Pending JP2023182667A (ja) 2019-05-14 2023-09-27 エルトロンボパグの投与計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023166306A Pending JP2023182667A (ja) 2019-05-14 2023-09-27 エルトロンボパグの投与計画

Country Status (9)

Country Link
US (1) US20220313663A1 (cg-RX-API-DMAC7.html)
EP (1) EP3968984A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022537883A (cg-RX-API-DMAC7.html)
KR (1) KR20220035036A (cg-RX-API-DMAC7.html)
AU (2) AU2019445762A1 (cg-RX-API-DMAC7.html)
CA (1) CA3140137A1 (cg-RX-API-DMAC7.html)
IL (1) IL288078A (cg-RX-API-DMAC7.html)
MX (1) MX2021013971A (cg-RX-API-DMAC7.html)
WO (1) WO2020231407A1 (cg-RX-API-DMAC7.html)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201406373A (zh) * 2012-06-29 2014-02-16 Shionogi & Co 含有具有血栓形成素受體促效作用之化合物之醫藥組合物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"History of Changes for Study: NCT03524612, A Study to Assess the Ability of Eltrombopag to Induce Su", CLINICAL TRIALS.GOV ARCHIVE [ONLINE], JPN6023011763, 7 May 2019 (2019-05-07), ISSN: 0005022722 *
AM. J. HEMATOL., vol. 90, no. 3, JPN6023011761, 2015, pages 40 - 43, ISSN: 0005022719 *
BLOOD, vol. 126, no. 23, JPN6023011762, 2015, pages 1054, ISSN: 0005022720 *
THER ADV DRUG SAF, vol. 9, no. 6, JPN6023011764, 2018, pages 263 - 285, ISSN: 0005022721 *
TRANSFUSION, vol. 53, JPN6023011760, 2013, pages 2807 - 2812, ISSN: 0005022718 *

Also Published As

Publication number Publication date
JP2023182667A (ja) 2023-12-26
AU2019445762A1 (en) 2021-12-09
MX2021013971A (es) 2022-04-01
AU2023274065A1 (en) 2023-12-14
US20220313663A1 (en) 2022-10-06
IL288078A (en) 2025-01-01
CA3140137A1 (en) 2020-11-19
WO2020231407A1 (en) 2020-11-19
KR20220035036A (ko) 2022-03-21
EP3968984A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
Yeh et al. Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology
Touhami et al. Expert opinion on the use of biological therapy in non-infectious uveitis
Do et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema
Jiang et al. Update on the use of anti-VEGF intravitreal therapies for retinal vein occlusion
JP6746495B2 (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
JP7295305B2 (ja) ループス腎炎の治療のための改善されたプロトコル
RU2017120437A (ru) Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r
TWI786636B (zh) 用於治療葡萄膜炎及黃斑水腫之包含il6r抗體的組合物與其使用方法
KR102373289B1 (ko) 지속성 부종을 갖는 삼출성 노인성 황반변성을 치료하기 위한 시롤리무스의 용도
Yuan et al. Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
JP2024530954A5 (cg-RX-API-DMAC7.html)
Meltzer et al. New intranasal formulations for the treatment of allergic rhinitis.
US20170224815A1 (en) Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition
Kreutzer et al. Intravitreal ranibizumab versus isovolemic hemodilution in the treatment of macular edema secondary to central retinal vein occlusion: twelve-month results of a prospective, randomized, multicenter trial
JP2023182667A (ja) エルトロンボパグの投与計画
Narayanan et al. Corticosteroids and anti-complement therapy in retinal diseases
WO2020231408A1 (en) Eltrombopag dosing regimen
Buchholz et al. Approach for Macular Edema
Patel et al. Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a study
Goel et al. Clinical Trials in Retinal Vascular Occlusions
Dalal et al. P028 Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders
HK40106641A (en) Anti-ctla-4 antibody dosing regimens
Delaney et al. Emerging treatments for non-infectious uveitis
Dalton et al. Ranibizumab achieves higher BCVA gains for BRVO in COMRADE-B.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220509

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220922

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230605

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230928